Test Catalog

Take Our Survey

Test ID: PNEOE    
Paraneoplastic Autoantibody Evaluation, Spinal Fluid

Method Description Describes how the test is performed and provides a method-specific reference

Indirect Immunofluorescence Assay (IFA):

The patient's sample is tested by a standardized IFA that uses a composite frozen section of mouse cerebellum, kidney, and gut tissues. After incubation with sample and washing, fluorescein-conjugated goat antihuman IgG is applied. Neuron-specific autoantibodies are identified by their characteristic fluorescence staining patterns. Autoantibody of antineuronal nuclear antibody-type 1 (ANNA-1) specificity is pan-neuronal in reactivity; it binds to the cytoplasm and nucleus (sparing nucleolus) of central and peripheral nervous system neurons. Autoantibody of ANNA-2 specificity has a similar binding pattern but reactivity is restricted to neurons of the central nervous system; neurons of the peripheral nervous system are nonreactive. Autoantibody of Purkinje cell cytoplasmic antibody (PCA)-1 specificity bind distinctively to endoplasmic reticulum in Purkinje cells, molecular neurons, and other large neurons in the central and peripheral nervous system. Samples that are scored positive for any neuronal nuclear or cytoplasmic autoantibody are titrated to an endpoint on mouse Purkinje cells or peripheral neurons. Interference by coexisting non-neuron-specific autoantibodies can usually be eliminated by serologic absorption. Occasionally Western blot analysis is required.(Yu Z, Kryzer TJ, Griesmann GE, Kim KK, et al: CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001;49:146-154)


Western Blot:

Western blot testing is indicated in the infrequent situation that interference by coexisting nonneuronal-specific autoantibodies precludes IFA interpretation. It is not cost-effective for routine serologic screening. However, results obtained by Western blot analyses in Mayo Clinic's Neuroimmunology Laboratory have shown 100% concordance with IFA results for PCA-1, and superior sensitivity of the IFA for detection of ANNA-1 and ANNA-2.


An aqueous extract of adult rat cerebellar proteins is used as the source of neuronal antigens on the paraneoplastic autoantibody Western blot. Western blot is performed on denatured and reduced proteins separated by electrophoresis on 10% polyacrylamide gel.(Vernino S, Lennon VA: New Purkinje cell antibody [PCA-2]: marker of lung cancer-related neurological autoimmunity. Ann Neurol 2000 March;47[3]:297-305). Full-length recombinant human CRMP-5 antigen is used to confirm CRMP-50IgG.(Yu Z, Kryzer TJ, Griesmann GE, et al: CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001 February;49[2]:145-154). Denatured full-length recombinant human amphiphysin protein is used to confirm amphiphysin antibody.


Radioimmunoassay (RIA) :

(125)I-labeled recombinant human GAD65 and nonimmune human serum are incubated with the patient's diluted cerebrospinal fluid. Antihuman IgG and IgM are then added to form an immunoprecipitate. After washing the precipitated immune complexes, specific antibodies are detected by counting gamma-emission from the pellet's bound I-GAD65.(Walikonis JE, Lennon VA: Radioimmunoassay for glutamic acid decarboxylase [GAD65] autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus. Mayo Clin Proc 1998 December;73[12]:1161-1166)


Cell Binding Assay (CBA):

Patient serum is applied to a composite slide containing transfected and nontransfected HEK-293 cells. After incubation and washing, fluorescein-conjugated goat antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: EUROIMMUN AG. Stocker W. et al. Differenzierte Autoantikorper-Diagnostik mit BIOCHIP-Mosaiken. U Conrad, K. [Hrsg] Autoantikorper. Pabst-Verlag [1998] 78-99)

PDF Report Indicates whether the report includes an additional document with charts, images or other enriched information


Day(s) and Time(s) Test Performed Outlines the days and times the test is performed. This field reflects the day and time the sample must be in the testing laboratory to begin the testing process and includes any specimen preparation and processing time required before the test is performed. Some tests are listed as continuously performed, which means assays are performed several times during the day.

ANNA-1, ANNA-2, ANNA-3, AGNA-1, PCA-1, PCA-2, PCA-Tr, Amphiphysin, CRMP-5-IgG, NMDIC, AMPIC, GABIC: Monday through Friday; 12 p.m. and 5 p.m.

Paraneoplastic autoantibody Western blot confirmation, CRMP-5-IgG Western blot, amphiphysin Western blot: Monday through Friday; 8 a.m.

NMO/AQP4-IgG CBA, NMDCC, AMPCC, GABCC: Monday through Friday; 4 a.m.

GAD65, VGKC-complex antibody: Monday through Friday; 2 a.m.

Analytic Time Defines the amount of time it takes the laboratory to setup and perform the test. This is defined in number of days. The shortest interval of time expressed is "same day/1 day," which means the results may be available the same day that the sample is received in the testing laboratory. One day means results are available 1 day after the sample is received in the laboratory.

3 days if negative/5 days if positive

Maximum Laboratory Time Defines the maximum time from specimen receipt at Mayo Medical Laboratories until the release of the test result

8 days

Specimen Retention Time Outlines the length of time after testing that a specimen is kept in the laboratory before it is discarded

28 days

Performing Laboratory Location The location of the laboratory that performs the test